These studies highlight the mechanistic basis for combining CDK4/6 inhibitors and PD-1/PD-L1 inhibitors as this combinatorial approach stimulates an immunogenic tumor microenvironment and primes cancers for PD1/PD-L1 immune checkpoint blockade. Here, CD274 is linked to cancer.